Drug Utilization in a Real World Cohort with Progressive Supranuclear Palsy
Objective: To evaluate the frequency of prescription medications commonly associated with the management of PSP in the community. Background: Progressive Supranuclear Palsy (PSP) is a…Skin in the game: Small fiber neuropathy in Parkinson’s disease and atypical parkinsonisms.
Objective: The aim of our study was to compare somatic and autonomic small fiber density, through skin biopsy, in Parkinson's disease (PD) and atypical parkinsonisms…Deciphering Corticobasal Syndrome: are clinical features and FDG-PET imaging capable of predicting amiloyd status?
Objective: The present study aimed at establishing clinical and brain functional patterns at FDG-PET that could distinguish Corticobasal Syndrome(CBS) variants due to AD from Tau pathology based on Pittsburgh Compound…Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways
Objective: To investigate the role and mechanism of C3a receptor in okadaic acid（OA） induced SH-SY5Y cells tau hyperphosphorylation model Background: Neurofibrillary tangles aggregated from hyperphosphorylated…Heavy metals implicated in a geographical cluster of progressive supranuclear palsy induce tau accumulation and apoptotic cell death in cultured neurons
Objective: To test the hypothesis that certain metals may cause cellular damage suggesting tauopathy. This is an early step in testing the hypothesis that environmental…Cortical and subcortical atrophy in typical and variant Parkinson-plus syndromes: PROSPECT-M-UK study
Objective: To investigate grey matter volume in typical and variant Parkinson-plus syndromes, to correlate these with disease severity, and to assess regional atrophy within disease…A panel of CSF and plasma biomarkers reveals novel biological insights into atypical parkinsonian syndromes
Objective: Our study aims to identify diagnostic markers of atypical parkinsonian disorders that offer novel insights into these conditions. In particular, we wish to use…Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up
Objective: To identify clinical characteristics, predictors and biomarkers of pain at baseline and after a two-year follow-up period in newly diagnosed drug-naïve Parkinson's Disease (PD)…Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…Tau and α-synuclein autoantibodies as potential biomarkers for Parkinson’s and Alzheimer’s diseases
Objective: To investigate the value of the naturally occurring serum AIAs of α-synuclein (α-syn) and tau, proteins as potential biomarker for diagnosis of PD in…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 13
- Next Page »